NCT02395770 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Desmeules F, Minville L, Riederer B, Côté CH, Frémont P
Acromio-humeral distance variation measured by ultrasonography and its association with the outcome of rehabilitation for shoulder impingement syndrome. Clin J Sport Med. 2004 Jul;14(4):197-205.
Ngomo S, Mercier C, Bouyer LJ, Savoie A, Roy JS
Alterations in central motor representation increase over time in individuals with rotator cuff tendinopathy. Clin Neurophysiol. 2015 Feb;126(2):365-71. doi: 10.1016/j.clinph.2014.05.035. Epub 2014 Jun 21.
Roy JS, Moffet H, Hébert LJ, Lirette R
Effect of motor control and strengthening exercises on shoulder function in persons with impingement syndrome: a single-subject study design. Man Ther. 2009 Apr;14(2):180-8. doi: 10.1016/j.math.2008.01.010. Epub 2008 Mar 20.
Roy JS, Moffet H, McFadyen BJ
The effects of unsupervised movement training with visual feedback on upper limb kinematic in persons with shoulder impingement syndrome. J Electromyogr Kinesiol. 2010 Oct;20(5):939-46. doi: 10.1016/j.jelekin.2009.10.005. Epub 2009 Nov 8.

Effects of a Movement Training Oriented Rehabilitation Program on Symptoms, Functional Limitations and Acromiohumeral Distance in Individuals With Subacromial Pain Syndrome

Details for clinical trial NCT02395770

Clinical trial NCT02395770 - References